HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
2024 Cantor Global Healthcare Conference on Tuesday, September 17th at 8:35 a.m. ET
TD Cowen's Chronic Urticaria Summit on Friday, September 20th at 10:00 a.m. ET
Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
This email address is being protected from spambots. You need JavaScript enabled to view it.
Patrick Till
Meru Advisors
(484) 788-8560
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$23.85 |
| Daily Change: | -0.90 -3.64 |
| Daily Volume: | 1,570,803 |
| Market Cap: | US$1.580B |
October 30, 2025 August 19, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
